Background: Artificial intelligence (AI) is transforming healthcare, yet little is known about Chinese oncologists' attitudes towards AI. This study investigated oncologists' knowledge, perceptions, and acceptance of AI in China.
Methods: A cross-sectional online survey was conducted among 228 oncologists across China. The survey examined demographics, AI exposure, knowledge and attitudes using 5-point Likert scales, and factors influencing AI adoption. Data were analyzed using descriptive statistics and chi-square tests.
Results: Respondents showed moderate understanding of AI concepts (mean 3.39/5), with higher knowledge among younger oncologists. Only 12.8% used ChatGPT. Most (74.13%) agreed AI is beneficial and could innovate healthcare, 52.19% respondents expressed trust in AI technology. Acceptance was cautiously optimistic (mean 3.57/5). Younger respondents (∼30) show significantly higher trust ( = 0.004) and acceptance ( = 0.009) of AI compared to older respondents, while trust is significantly higher among those with master's or doctorate vs. bachelor's degrees ( = 0.032), and acceptance is higher for those with prior IT experience ( = 0.035).Key drivers for AI adoption were improving efficiency (85.09%), quality (85.53%), reducing errors (84.65%), and enabling new approaches (73.25%).
Conclusions: Chinese oncologists are open to healthcare AI but remain prudently optimistic given limitations. Targeted education, especially for older oncologists, can facilitate AI implementation. AI is largely welcomed for its potential to augment human roles in enhancing efficiency, quality, safety, and innovations in oncology practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405309 | PMC |
| http://dx.doi.org/10.3389/fdgth.2024.1371302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cuproplasia and cuproptosis, two sides of the coin.
Cancer Commun (Lond)
January 2025
Department of Medical Oncology, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Copper is an essential micronutrient in the human body, mainly acting as a crucial cofactor required for a wide range of physiological processes across nearly all cell types. Recent advances revealed that tumor cells seize copper to fulfill their rapid proliferation, metastasis, immune evasion, and so on by reprogramming the copper regulatory network, defined as cuproplasia. Thus, targeting copper chelation to reduce copper levels has been considered a rational tumor therapy strategy.
View Article and Find Full Text PDFNeeds Assessment to Guide the Development of a Pediatric Survivorship Program to Promote the Physical and Psychological Well-being of Children After Cancer Treatment.
Cancer Nurs
January 2025
Author Affiliations: The School of Nursing, The Hong Kong Polytechnic University (Dr Chung); and The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong (Dr Li), Hong Kong Special Administrative Region, China; School of Nursing, School of Health and Social Care, Edinburgh Napier University, United Kingdom (Dr Ching); Hong Kong Sanatorium and Hospital (Ms Chiu); Paediatric Haematology and Oncology (Ms Mak) and Department of Paediatric and Adolescent Medicine (Dr Chan), Hong Kong Children's Hospital, Hong Kong Special Administrative Region, China.
Background: Studies have provided insights into the major challenges and needs of young children who survive cancer. Many such challenges are related to a lack of support during the patient's transition back to normal life. Survivorship programs are designed to help survivors cope with potential late effects of treatment and to provide psychosocial support.
View Article and Find Full Text PDFEnsemble machine learning models for lung cancer incidence risk prediction in the elderly: a retrospective longitudinal study.
BMC Cancer
January 2025
Institute of Medical Information, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Identifying high risk factors and predicting lung cancer incidence risk are essential to prevention and intervention of lung cancer for the elderly. We aim to develop lung cancer incidence risk prediction model in the elderly to facilitate early intervention and prevention of lung cancer.
Methods: We stratified the population into six subgroups according to age and gender.
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer.
Lung Cancer
January 2025
Lung Cancer Clinic, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
The peri-operative management of non-small cell lung cancer (NSCLC) in earlier stage disease has seen significant advances in recent years with the incorporation of immune checkpoint inhibitors and targeted therapy. However, many unanswered questions and challenges remain, including the application of clinical trial data to routine clinical practice. Recognising the unique demographic profile of Asian patients with NSCLC and heterogeneous healthcare systems, the Asian Thoracic Oncology Research Group (ATORG) convened a consensus meeting in Singapore on 26 April 2024 to discuss relevant issues spanning diagnostic testing to post-neoadjuvant treatment considerations and future directions.
View Article and Find Full Text PDFNovel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor.
Oncologist
December 2024
Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, People's Republic of China.
Background: Both novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) and pertuzumab and trastuzumab (HP) combined with chemotherapy(C) regimens are the choice of treatment for HER2 positive metastatic breast cancer (MBC) after tyrosine kinase inhibitors (TKIs). Our team's previous research has shown significant therapeutic effects of novel anti-HER2 ADCs in patients with TKIs treatment failure. Unfortunately, there is currently no data available to compare novel anti-HER2 ADCs with HP combined with chemotherapy regimens.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!